Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder; and Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures. The company’s proprietary pipeline of complex molecule products includes AQST-108, which is in phase 2, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, which is in phase 3, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.